"Lu AA47070 is a very promising compound with a unique profile and has the potential to make a significant difference to for instance patients suffering from Parkinson's disease," says Peter HÃ¸ngaard Andersen, Head of Research at Lundbeck. He continues: "Lu AA47070 is discovered at Lundbeck and is our first compound within the neurology area from our internal research."
About Parkinsons Disease
Parkinson's disease is a chronic, progressive neurodegenerative condition. The exact cause of Parkinson's disease is not known and is believed to be multifactorial involving genes, environmental factors and aging.
Symptoms include tremor, slowness of movement, stiffness, gait and posture problems. As the disease progresses, symptoms worsen, the patient is likely to experience motor complications. Eventually, the disease impairs the patient's ability to function.
Parkinson's disease affects men and women equally, and an estimated four million people worldwide suffer from the disease. The disease typically occurs at a late age, affecting approx. 1% of the population over the age of 65. In 2006, the worldwide sales for drugs to treat Parkinson's disease reached USD 3.1 billion.
H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com.